Showing results (591-600 of 774) with videos related to

Sort By:
Pageof 78
The New England Journal of Medicine|December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisDominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic ArthritisDésirée van der Heijde, Robert B Landewé, Philip J Mease, et al.
The Journal of Nutrition|December 25, 2008
Plasma adiponectin concentrations are associated with body composition and plant-based dietary factors in female twinsAedin Cassidy, Paula Skidmore, Eric B Rimm, et al.
ACR Open Rheumatology|January 21, 2020
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 StudyKarel Pavelka, Alan J Kivitz, Eva Dokoupilova, et al.
Annals of Internal Medicine|December 1, 1994
Lack of HIV transmission in the practice of a dentist with AIDSH W Jaffe, J M McCurdy, M L Kalish, et al.
Journal of Intensive Care Medicine|June 26, 2023
Timing of Transport of Patients with COVID-19Jane M Hayes, Jeremy B Richards, Michael A Frakes, et al.
Environmental Research|September 24, 2022
Sex-biased expression of the TLR7 gene in severe COVID-19 patients: Insights from transcriptomics and epigenomicsA Gómez-Carballa, J Pardo-Seco, S Pischedda, et al.
Arthritis Research & Therapy|July 19, 2006
Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseasesYoshioki Yamasaki, Sonali Narain, Liza Hernandez, et al.
The Journal of Urology|October 1, 1988
Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinomaF M Debruyne, L Denis, G Lunglmayer, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
Pageof 78